Depomed soars after royalty, milestone deal with PDL

Investors appear to be cheering Depomed's (DEPO) move to sell diabetes royalty and milestone rights to PDL BioPharma (PDLI).

DEPO +13% premarket

More on the deal here

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs